Shukuya T, Takahashi K, Shintani Y, Miura K, Sekine I, Takayama K, Inoue A, Okamoto I, Kiura K, Kawaguchi T, Yamamoto N, Miyaoka E, Yoshino I, Date H (2023) Epidemiology, risk factors and impact of cachexia on patient outcome: results from the Japanese Lung Cancer Registry Study. J Cachexia Sarcopenia Muscle 14(3):1274–1285. https://doi.org/10.1002/jcsm.13216

Article  PubMed  PubMed Central  Google Scholar 

Watanabe H, Oshima T (2023) The latest treatments for cancer cachexia: an overview. Anticancer Res 43(2):511–521. https://doi.org/10.21873/anticanres.16188

Article  CAS  PubMed  Google Scholar 

Cordeiro LAF, Silva TH, de Oliveira LC, Neto JFN (2020) Systemic inflammation and nutritional status in patients on palliative cancer care: a systematic review of observational studies. Am J Hosp Palliat Care 37(7):565–571. https://doi.org/10.1177/1049909119886833

Article  PubMed  Google Scholar 

Wilkinson TJ, Miksza J, Yates T, Lightfoot CJ, Baker LA, Watson EL, Zaccardi F, Smith AC (2021) Association of sarcopenia with mortality and end-stage renal disease in those with chronic kidney disease: a UK Biobank study. J Cachexia Sarcopenia Muscle 12(3):586–598. https://doi.org/10.1002/jcsm.12705

Article  PubMed  PubMed Central  Google Scholar 

Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, Mambet C, Anton G, Tanase C (2018) Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res 2018:2180373. https://doi.org/10.1155/2018/2180373

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang AY, Kovesdy CP (2021) Nutrition and obesity impacts on kidney health. Contrib Nephrol 199:24–42. https://doi.org/10.1159/000517669

Article  CAS  PubMed  Google Scholar 

Yoon S, Ko NG, Lee YJ (2024) Geriatric nutritional risk index as a possible predictor of decline in kidney function in older people. Ann Geriatr Med Res 28(2):164–170. https://doi.org/10.4235/agmr.23.0215

Article  PubMed  PubMed Central  Google Scholar 

Zha Y, Qian Q (2017) Protein nutrition and malnutrition in CKD and ESRD. Nutrients. https://doi.org/10.3390/nu9030208

Article  PubMed  PubMed Central  Google Scholar 

Zhang J, Xiao X, Wu Y, Yang J, Zou Y, Zhao Y, Yang Q, Liu F (2022) Prognostic nutritional index as a predictor of diabetic nephropathy progression. Nutrients. https://doi.org/10.3390/nu14173634

Article  PubMed  PubMed Central  Google Scholar 

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402(6762):656–660. https://doi.org/10.1038/45230

Article  CAS  PubMed  Google Scholar 

Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M (2000) Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141(11):4255–4261. https://doi.org/10.1210/endo.141.11.7757

Article  CAS  PubMed  Google Scholar 

Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S (2001) A role for ghrelin in the central regulation of feeding. Nature 409(6817):194–198. https://doi.org/10.1038/35051587

Article  CAS  PubMed  Google Scholar 

Tschöp M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407(6806):908–913. https://doi.org/10.1038/35038090

Article  PubMed  Google Scholar 

Fujimura K, Wakino S, Minakuchi H, Hasegawa K, Hosoya K, Komatsu M, Kaneko Y, Shinozuka K, Washida N, Kanda T, Tokuyama H, Hayashi K, Itoh H (2014) Ghrelin protects against renal damages induced by angiotensin-II via an antioxidative stress mechanism in mice. PLoS ONE 9(4):e94373. https://doi.org/10.1371/journal.pone.0094373

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yanagimoto Y, Takiguchi S, Miyazaki Y, Makino T, Takahashi T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Hosoda H, Kangawa K, Mori M, Doki Y (2016) Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: a prospective randomised phase II trial. Br J Cancer 114(12):1318–1325. https://doi.org/10.1038/bjc.2016.160

Article  CAS  PubMed  PubMed Central  Google Scholar 

Azushima K, Uneda K, Wakui H, Ohki K, Haruhara K, Kobayashi R, Haku S, Kinguchi S, Yamaji T, Minegishi S, Ishigami T, Yamashita A, Tamura K (2019) Effects of rikkunshito on renal fibrosis and inflammation in angiotensin II-infused mice. Sci Rep 9(1):6201. https://doi.org/10.1038/s41598-019-42657-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Currow DC, Abernethy AP (2014) Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncol 10(5):789–802. https://doi.org/10.2217/fon.14.14

Article  CAS  PubMed  Google Scholar 

Zhang H, Garcia JM (2015) Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opin Pharmacother 16(8):1245–1253. https://doi.org/10.1517/14656566.2015.1041500

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ono Pharmaceutical Co. L (2023) The drug interview form of Anamorelin Hydrochloride (ADLUMIZ®). In: ed

Garcia JM, Friend J, Allen S (2013) Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 21(1):129–137. https://doi.org/10.1007/s00520-012-1500-1

Article  PubMed  Google Scholar 

Garcia JM, Polvino WJ (2007) Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 12(5):594–600. https://doi.org/10.1634/theoncologist.12-5-594

Article  CAS  PubMed  Google Scholar 

Garcia JM, Polvino WJ (2009) Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 19(3):267–273. https://doi.org/10.1016/j.ghir.2008.12.003

Article  CAS  PubMed  Google Scholar 

Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, Aoe K, Tsuji T, Takiguchi Y, Takayama K, Komura N, Takiguchi T, Eguchi K (2018) Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124(3):606–616. https://doi.org/10.1002/cncr.31128

Article  CAS  PubMed  Google Scholar 

Takayama K, Katakami N, Yokoyama T, Atagi S, Yoshimori K, Kagamu H, Saito H, Takiguchi Y, Aoe K, Koyama A, Komura N, Eguchi K (2016) Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer 24(8):3495–3505. https://doi.org/10.1007/s00520-016-3144-z

Article  PubMed  PubMed Central  Google Scholar 

Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17(4):519–531. https://doi.org/10.1016/s1470-2045(15)00558-6

Article  CAS  PubMed  Google Scholar 

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489–495. https://doi.org/10.1016/s1470-2045(10)70218-7

Article  PubMed  Google Scholar 

Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S (2010) Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis 56(1):32–38. https://doi.org/10.1053/j.ajkd.2010.02.344

Article  PubMed  Google Scholar